Health Information Exchanges and The Nhin
Signs of Continued Progress on Many Fronts
| Publication Date | June 2008 |
|---|---|
| Publisher | IDC |
| Product Type | Report |
| Pages | 17 |
| ISBN Number | not applicable |
| Product Code | IDC04359 |
Summary
This Health Industry Insights report summarizes recent progress in the adoption of both electronic medical records (EMR) and electronic health records (EHR) nationwide and the analyzes the effects of recent events at national, state, regional, and local levels to the ultimate success of the National Health Information Network (NHIN), arguably one of the most visible eHealth initiatives of the Bush administration.
Because the need for providers to electronically access patient medical history data is more relevant from across town, rather than across the continent, questions persist as to the ultimate value of the NHIN. "Nevertheless, the NHIN has become a symbol of the Bush eHealth policies; one that keeps the concept of HIT highly visible on the national stage and provides a 'test bed' for the development of standards to facilitate data exchange at any regional level. And this, in and of itself, is not a bad thing," said Marc Holland, program director for Healthcare Provider IT Research.
Content
- Health Industry Insights Opinion
- In This Report
- Situation Overview
- NHIN Phase 1
- NHIN Phase 2
- Current Environment
- Figure: NAMCS EMR Adoption Survey, 2001–2006: Overall Adoption Rates
- Figure: NAMCS EMR Adoption Survey, 2006: Adoption Rates by Practice Size
- Figure: AHA EMR Implementation Status by Bed Complement
- Table: AHA Core EMR Functions
- Six Additional NHIN Phase 2 Contract Awards, May 2008
- HealthBridge
- Kaiser Permanente
- The Cleveland Clinic
- Others
- Future Outlook
- Essential Guidance
- Actions to Consider
- Closing Thoughts
- Learn More
- Related Research
- Synopsis
About this Product
Delivery Details
PDF:Immediate delivery
Related Products
- AstraZeneca’s Crestor Could Revolutionise Heart Disease Treatment >>
- Sanofi-Aventis and Pfizer Stop Development of a Class of Anti-obesity drugs >>
- Pharma Companies turn Webwards to Recruit Patients as 90% of Clinical Trials Face Delay >>
- Have your Healthcare Costs Reduced with Personalized Healthcare >>
Pharma & Healthcare
- Animal / Veterinary
- Biotechnology
- Cardiovascular
- Chemicals
- Company Financials
- Company Reports (Pharmaceutical)
- Country Reports (Pharmaceutical)
- Deals & Alliances
- Dental
- Diagnostics
- Dietary
- Diseases
- Drug Delivery
- Drug Discovery
- Finance / Investment
- General Industry
- Generic Drugs
- Healthcare
- IT & eHealth
- Management / Strategy
- Medical Devices
- Medical Supplies
- OTC drugs
- Pharmacy
- Prescription Drugs
- Production / Manufacturing
- Regulation & Policy
- Research (R&D)
- Sales & Marketing
- Technology
- Therapeutic
- Treatments
call +44 (0) 20 7060 7474
or email us
Resources
Why Report Buyer?
Advertising/Affiliates
View Our Publishers
News
About Us
Market Publishers
Meet Us
Jobs
Contact Us
Categories and Subcategories















